OssDsign’s clinical study TOP FUSION is now fully enrolled
Uppsala, April 25, 2022. OssDsign AB (publ.) today announces that the company’s clinical study TOP FUSION is fully enrolled and patient follow-up will continue to run over 24 months.The trial will primarily evaluate the safety and efficacy of OssDsign Catalyst in patients undergoing spinal fusion surgery. The study’s primary endpoint will be assessed by the rate of bone fusion as well as a lack of device-related adverse events. “We are very pleased to have completed the enrollment in this clinical trial and delivered on yet another major milestone. As TOP FUSION will provide key